Cardiovascular outcomes and safety of SGLT2 inhibitors in rheumatic diseases: a systematic review of evidence predominantly from systemic lupus erythematosus and systemic sclerosis

Seminars in Arthritis and Rheumatism · Elsevier

The publisher did not provide an abstract — full text is available via the link below.

Read at publisher →

Similar articles